Publications
Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib GalleryComparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib
Meiqi Wu1, Yanyu Wang2, Qiao Yang1, Xuezhu Wang1, Xu Yang2, Haiqun Xing1, Xinting Sang2, Xiang Li3, Haitao Zhao2, Li Huo4 Abstract Fibroblast activation protein contributes to immunosuppression and resistance to immunotherapies. This study aimed to compare baseline 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT and 18F-FDG [...]
Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis GalleryDiagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis
Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis
Alessio Rizzo1, Manuela Racca1, Federico Garrou2, Elisabetta Fenocchio3, Luca Pellegrino4, Domenico Albano5, Francesco Dondi5, Francesco Bertagna5, Salvatore Annunziata6, Giorgio Treglia7,8,9 Abstract Various papers have introduced the use of positron emission tomography (PET) with [68Ga]Ga-radiolabeled fibroblast-activation protein inhibitor (FAPi) radiopharmaceuticals in different subtypes of gastric [...]
FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease
Yuriko Mori 1, Katharina Dendl 1, Jens Cardinale 1, Clemens Kratochwil 1, Frederik L Giesel # 1, Uwe Haberkorn # 1 Abstract Gallium 68 (68Ga)-labeled fibroblast activation protein (FAP) inhibitor (FAPI) PET is based on the molecular targeting of the FAP, which is known to be highly expressed in the major cell population in tumor stroma, termed [...]
Novel 68Ga-FAPI PET/CT offers oncologic staging without COVID-19 vaccine-related pitfalls
Tristan T Demmert 1, Ines Maric 1, Kelsey L Pomykala 2, Katharina Lueckerath 1, Jens Siveke 3, Benedikt M Schaarschmidt 4, Rainer Hamacher 3, Ken Herrmann 1, Wolfgang P Fendler 1 Abstract In the setting of ongoing SARS-CoV-2 vaccination, vaccine-related tracer uptake in locoregional lymph nodes has become a well-known issue in tumor staging by 18F-FDG PET/CT. 68Ga-FAPI PET/CT is a new oncologic [...]
Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer
Philipp Backhaus 1, Matthias C Burg 2, Inga Asmus 1, Michaela Pixberg 1, Florian Büther 1, Hans-Jörg Breyholz 1, Randy Yeh 3, Stefanie B Weigel 2, Patricia Stichling 2, Walter Heindel 2, Stefanie Bobe 4, Peter Barth 5, Joke Tio 6, Michael Schäfers 1 Abstract Rationale: Improving imaging-based response following neoadjuvant chemotherapy (NAC) in breast cancer assessment could obviate the need for histologic confirmation of pathological complete response (pCR) and facilitate de-escalation [...]
3-time-point PET-analysis of FAPI-46 in a variety of cancers
Mahnoosh Naeimi 1, Peter L Choyke 2, Katharina Dendl 1, Yuriko Mori 3, Fabian Staudinger 1, Tadashi Watabe 4, Stefan A Koerber 5, Manuel Röhrich 1, Juergen Debus 5, Clemens Kratochwil 1, Uwe A Haberkorn 1, Frederik L Giesel 1 Abstract Purpose: A growing family of 68Ga-FAPI Positron Emission Tomography (PET) probes have shown promise in imaging a variety of medical conditions. 68Ga-FAPI-46 in particular has emerged as unique for [...]